Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 24, 2021 16:05 ET | Source: MediWound Ltd.

MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds

YAVNE, Israel, March 24, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair...
February 25, 2021 16:01 ET | Source: MediWound Ltd.

MediWound to Participate in Upcoming March Investment Conferences

YAVNE, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair...
February 25, 2021 07:00 ET | Source: MediWound Ltd.

MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results

Fourth Quarter Revenues of $6.7 Million - Up 23%and Full-Year 2020 Revenues of $21.8 Million - Product Revenue Up 117% Conference call begins today at 8:30 am ET YAVNE, Israel, Feb. 25, 2021 ...
February 22, 2021 06:30 ET | Source: MediWound Ltd.

MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer

Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021 An Investigator-Initiated Trial Will Run in Parallel YAVNE, Israel,...
February 16, 2021 16:05 ET | Source: MediWound Ltd.

MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021

YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
February 10, 2021 16:15 ET | Source: MediWound Ltd.

MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

YAVNE, Israel, Feb. 10, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
January 11, 2021 07:00 ET | Source: MediWound Ltd.

MediWound Provides Progress Update on Its EscharEx Clinical Development Program

Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients Interim Assessment Expected in Mid-2021 and Completion of Enrollment by Year-End 2021 Protocol Submitted to FDA for Pharmacology...
January 05, 2021 07:00 ET | Source: MediWound Ltd.

MediWound to Participate in Upcoming Investor Conferences in January

YAVNE, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
December 21, 2020 07:30 ET | Source: MediWound Ltd.

Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent

YAVNE, Israel, Dec. 21, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
December 14, 2020 16:15 ET | Source: MediWound Ltd.

MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group

YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...